Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease

Renal Failure

Volumn 36, Issue 2, 2014, Pages 225-231

  Sakai, Yukinao ^a   Otsuka, Tomoyuki ^a   Ohno, Dai ^a   Murasawa, Tsuneo ^a   Sato, Naoki ^a   Tsuruoka, Shuichi ^b  

^a NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Allopurinol; Chronic kidney disease; Febuxostat; Hyperuricemia

Indexed keywords

ALLOPURINOL; AMINOTRANSFERASE; CREATININE; FEBUXOSTAT; URIC ACID;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERURICEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; CREATININE; ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERURICEMIA; KIDNEY; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; THIAZOLES; URIC ACID;

EID: 84896695460     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.844622     Document Type: Article

References (22)

1. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13(6):537-566.
2. Japanese Society of Nephrology. CKD treatment guidance 2012 [Article in Japanese]. Tokyo: Tokyo Igakusha; 2012.
3. Yamanaka H; Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1018-1029.
4. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642-650.
5. Okamoto K. A new-generation uric acid production inhibitor febuxostat - comparison of the XO inhibition mechanism with allopurinol [Article in Japanese]. Yakuri to Chiryo. 2010; 38(11):955-962.
6. Kamatani N, Fujimori S, Hada T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol. 2011;17(4 Suppl 2):S13-S18.
7. Becker MA, Schumacher Jr HR, Espinoza LR, et al. The uratelowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978.
8. Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548.
9. Becker MA, Schumacher Jr HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New Engl J Med. 2005;353:2450-2461.
10. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful long term urate lowering with febuxostat or allopurinol in subjects with gout. J Rheum. 2009; 36(6):1273-1282.
11. Hanratty R, Chonchol M, Dickinson LM, et al. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrol Dial Transplant. 2010; 25(3):801-807.
12. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol. 2011;17(1):7-13.
13. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134-146.
14. Yu MA, Sa'nchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010; 28(6):1234-1242.
15. Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36(1):43-49.
16. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924-932.
17. Hiramitsu S, Ishiguro Y, Matsuyama H, et al. Investigation of the utility of febuxostat (Feburic- tablet) in patients with hyperuricemia - multi-center collaborative study by general practitioners [Article in Japanese]. Blood Pressure. 2012;19: 395-402.
18. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446.
19. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-1393.
20. Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med. 2011;51(1):179-184.
21. Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549-556.
22. Tsuda H, Kawada N, Kaimori JY, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. Biochem Biophys Res Commun. 2012;427(2):266-272.